<DOC>
	<DOCNO>NCT01278745</DOCNO>
	<brief_summary>All people heart transplant risk develop cardiac allograft vasculopathy ( CAV ) . CAV mean narrowing heart transplant vessel , associate poor heart transplant function . People develop antibody transplant high risk develop CAV . Infections , high cholesterol , rejection also increase risk develop CAV . People develop CAV usually receive another transplant .</brief_summary>
	<brief_title>Prevention Cardiac Allograft Vasculopathy Using Rituximab ( Rituxan ) Therapy Cardiac Transplantation</brief_title>
	<detailed_description>The purpose research study see study drug call rituximab ( Rituxan® ) prevent CAV . Rituximab destroy certain type white blood cell call B cell . B cell important cell immune system help body fight infection produce substance call antibody . B cell antibody produce also involved kind rejection organ transplantation . Rituximab decrease number B cell blood tissue . The goal study determine decrease B cell Rituximab prevent injury transplant heart .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion Criteria Initial Enrollment : Subject must able understand provide informed consent ; Male Female , 18 75 year age ; Candidate primary heart transplant ( e.g. , listed heart transplant ) ; Historical panel reactive antibody ( PRA ) less 30 % ; Calculated GFR ≥ 40 mL/minute use Chronic Kidney Disease Epidemiology Collaboration equation ( CKDEPI ) ; Female male subject reproductive potential , must agree use FDA approve method birth control duration study Inclusion Criteria Randomization / Posttransplant : Negative PRA within 12 week prior transplant ( Local HLA Center Testing ) use one following : One Lambda 's LABScreen® Mixed Class I &amp; II ( presence absence ) , Less 10 % One Lambda 's LABScreen® PRA Class I II MFI &lt; 2000 , Calculated panel reactive antibody ( cPRA ) less 10 % LABScreen® Single Antigen test ( AntiHLAA , B , DR , DQ ) . The antigen report include MFI &gt; 2000 . The Luminex GenProbe bead equivalent One Lambda may use alternative ; Calculated GFR ≥ 40mL/minute use CKDEPI time randomization ; Serum immunoglobulin G ( IgG ) level great 500mg/dL within 90 day prior randomization ; Negative test HIV , HBsAg , HBcAb , HCV Ab within 12 month prior transplant . If documentation present support test perform past 12 month , blood sample collect prior transplant send local testing . Results may available randomization . If positive result , oversight committee review case provide recommendation . Female subject childbearing potential must negative pregnancy test . Exclusion Criteria Enrollment : Prior history organ transplantation ; Previous treatment Rituximab ( MabThera® / Rituxan ® ) ; Transplant physician intention use induction agent ; History severe allergic anaphylactic reaction humanize murine monoclonal antibody ; History severe reaction previous therapy IVIG ; Active systemic infection time enrollment ; Any history serologic positivity HIV , HBsAg , HBcAb , HCV Ab ; History le 5 year remission malignancy . Any history adequately treat insitu cervical carcinoma , adequately treat basal squamous cell carcinoma skin permit ; Any condition , opinion investigator , would interfere subject 's ability comply study requirement ; Use investigational drug within 4 week enrollment ; Currently breastfeed plan become pregnant timeframe study followup period . Exclusion Criteria Randomization/Posttransplant : Recipient multiple solid organ tissue transplant ; Previous treatment Rituximab ( MabThera® / Rituxan ® ) ; Use induction agent ; History severe allergic anaphylactic reaction humanize murine monoclonal antibody ; History severe reaction previous therapy IVIG ; Lack IV venous access ; Active systemic infection time randomization ; Any history serologic positivity HIV , HBsAg , HBcAb HCV Ab ; Any condition , opinion investigator , would interfere subject 's ability comply study requirement ; Use investigational drug within 4 week prior randomization ; Receipt live vaccine within 30 day prior randomization ; Currently breastfeed plan become pregnant timeframe study followup period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cardiac allograft vasculopathy ( CAV )</keyword>
	<keyword>prevention</keyword>
	<keyword>cardiac transplantation</keyword>
	<keyword>rituximab</keyword>
</DOC>